An acute respiratory infection (ARI) is the most common single reason for outpatient office visits and antibiotic prescriptions.
More than 90% of patients who present to their healthcare providers with the most common symptom of an ARI—an acute cough—have a syndrome caused by a virus.
Unnecessary use of antibiotics leads to antibiotic resistance, causing more than 25,000 deaths in the EU, and 700,000 globally.8-9 Antibiotic resistance results in costs over €1.5 billion in the EU and $20 billion in the U.S. annually.
Randox Laboratories is committed to continually improving health worldwide through the use of our revolutionary products and solutions. Our comprehensive portfolio is designed to provide efficient, high quality and reliable diagnostics in the widest variety of laboratory settings. In 2020 Randox launched a novel molecular assay for the simultaneous detection of SARS-COV-2 (COVID-19) and nine other respiratory pathogens.
Our diverse product offering also includes third party quality control, the world’s largest EQA scheme, high quality biochemistry reagents, clinical chemistry analysers and an extensive range of molecular diagnostic solutions.
Quidel Corporation (Nasdaq: QDEL) is a California-based leading diagnostic healthcare manufacturer serving to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system.
Roche are the world's number 1 in biotech with 17 biopharmaceuticals on the market. Over half of the compounds in our product pipeline are biopharmaceuticals, enabling them to deliver better-targeted therapies. For more information visit:
Lumos helps you develop and manufacture custom rapid Point-of-Care diagnostic solutions.
Lumos provides a unique offering to our partners by having the full range of expertise in house to deliver complete, commercially ready point-of-care solutions. Our goal is to enable point-of-care testing to be more accessible, facilitating the migration of diagnostic testing out of laboratories, directly to where it’s really needed.
We keep a finger on the pulse of the market to identify challenges affecting the uptake of point-of-care tests and keep abreast of new technologies that may help overcome those barriers. We have a highly experienced team that’s passionate about point-of-care diagnostics and ensuring we provide the best custom solutions for our partners.